Arcellx Stock

arcellx.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $235.48MM

Arcellx develops novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Arcellx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Arcellx’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Arcellx.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Drop in Short Interest
Arcellx, Inc. experienced a significant 7.8% drop in short interest in November, with short interest totalling approximately 5.07 million shares. The company also saw several changes in their institutional investors, with notable increases in holdings from FMR LLC, State Street Corp, Perceptive Advisors LLC, and BlackRock Inc. Analysts currently have a "buy" rating on the stock.
Updated on: Apr 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.